A novel breath test, measuring the immune response to the H1N1 flu virus, could help to ease future vaccine shortages by identifying the people who have already been infected with the flu virus…
Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
15
Jul |
Future Swine Flu Vaccination Shortages Could Be Reduced By Breath TestCategory: Swine Flu | Leave a Comment |
A novel breath test, measuring the immune response to the H1N1 flu virus, could help to ease future vaccine shortages by identifying the people who have already been infected with the flu virus…
|
27
Jul |
FDA Clears Prodesse’s ProFAST™+ Assay To Identify Three Strains Of Influenza A, Including 2009 H1N1Category: Swine Flu | Leave a Comment |
Gen-Probe Incorporated (Nasdaq: GPRO) announced that the U.S. Food and Drug Administration (FDA) has cleared for marketing Prodesse’s ProFAST™+ assay, making it the only FDA-cleared molecular diagnostic test to simultaneously detect and differentiate three common influenza A virus subtypes seasonal A/H1, seasonal A/H3, and 2009 H1N1…
|
26
Mar |
Surgical Masks Provided Effective Protection Of Health-Care Workers Against H1N1 According To StudyCategory: Swine Flu | Leave a Comment |
The effectiveness of ordinary surgical masks as opposed to respirators in protecting health care workers against the 2009 H1N1 influenza virus has been the subject of debate. An observational study published in the April 1, 2010 issue of Clinical Infectious Diseases, available online (http://www.journals.uchicago.edu/doi/full/10…
|
22
Mar |
Infrared Thermal Detection Systems Useful For Patient ScreeningCategory: Swine Flu | Leave a Comment |
Researchers at the University of Nebraska Medical Center (UNMC) found an Infrared Thermal Detection System (ITDS) to be a fast and effective fever screening tool in clinical settings during the H1N1 influenza pandemic. The ITDS detected fever in patients through split-second, non-contact skin temperature measurements…
|
24
Feb |
Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) For The First 2009 H1N1 Influenza Assay To Include MTMCategory: Swine Flu | Leave a Comment |
Longhorn Vaccines & Diagnostics announced it has been granted Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay™ in CLIA high complexity laboratories. …
|
5
Jan |
Cepheid Receives FDA Emergency Use Authorization (EUA) For First 2009 H1N1 Influenza Assay For CLIA ‘Moderate Complexity’ LaboratoriesCategory: Swine Flu | Leave a Comment |
Cepheid (Nasdaq: CPHD) announced it has been granted Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Xpert® Flu A Panel test. The test, which runs on Cepheid’s GeneXpert® System, identifies the 2009 H1N1 influenza virus in less than one hour…
|
30
Oct |
H1N1 Testing Data Presented At Infectious Diseases Society Of America ConferenceCategory: Swine Flu | Leave a Comment |
The Phoenix-based non-profit Translational Genomics Research Institute (TGen) has announced that, along with a business collaborator, it will submit a request to the U.S. Food and Drug Administration for emergency use of a new test to diagnose the 2009 H1N1 swine flu virus. Details about TGen’s test will be presented Sunday (Nov. 1) at the 47th annual meeting of the Infectious Diseases Society of America (IDSA), being held today through Sunday (Oct. 29-Nov. 1) in Philadelphia.
|
21
Oct |
When Detecting Abnormalities In Patients With H1N1 Virus, CT Scans Better Than X-RaysCategory: Swine Flu | Leave a Comment |
Computed tomography (CT) scans are better than standard radiography (X-rays) in showing the extent of disease in patients with the H1N1 virus, according to a study to be published online Oct. 21, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR. The study group consisted of seven patients with the H1N1 virus. All seven patients received chest X-rays and three patients had CT scans.
|
21
Oct |
Aethlon Medical Releases Medical Device Data Against The H1N1 Swine Flu VirusCategory: Swine Flu | Leave a Comment |
Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced that research studies have documented the Aethlon Hemopurifier® is effective in capturing the current pandemic strain of the H1N1 Swine Flu Virus. The Hemopurifier® is the first-in-class medical device able to selectively remove infectious viruses and immunosuppressive proteins from the bloodstream.
|
17
Oct |
FDA Issues Another Emergency Use Authorization For Commercial H1N1 Flu Test To Quest Diagnostics’ Focus DiagnosticsCategory: Swine Flu | Leave a Comment |
The U.S. Food and Drug Administration (FDA) issued a second emergency use authorization (EUA) to Focus Diagnostics, the infectious disease diagnostics business of Quest Diagnostics Incorporated (NYSE: DGX), for its 2009 H1N1 influenza virus test. With the EUA, Focus Diagnostics is the only company in the U.S.